Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04603196 · ClinicalTrials.gov registry record
Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis
A clinical trial of Multiple Sclerosis and Obstructive Sleep Apnea, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- 800
- Enrollment target
- 1
- Study location
NCT04603196: Recruiting study of Multiple Sclerosis and Obstructive Sleep Apnea, sponsored by Beth Israel Deaconess Medical Center.
NCT04603196 is a study of Multiple Sclerosis and Obstructive Sleep Apnea that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 800 participants, above the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (37% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04603196, a study of Multiple Sclerosis and Obstructive Sleep Apnea, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the influence of sleep apnea on clinical and radiological features of MS. Sleep apnea is associated with hypoxemia during sleep, which is likely detrimental to MS. Clinical data (MRI, lab results, medical history, labs, and sleep studies) of MS patients will be collected and analyzed. This will be done to study correlations between MRI, clinical data, lab studies and sleep studies. There is specific interest in the type of sleep apnea associated with MS, and whether MRI or clinical metrics of MS severity correlate with presence or absence of sleep apnea.
Primary Outcome
Home Sleep Study Data
Conditions Studied
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2019-06-20 |
| Est. Completion | 2030-06-20 |
What NCT04603196 shows while recruiting
NCT04603196 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (37% higher).
The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT04603196 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04603196 about?
NCT04603196 is a clinical study titled "Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis". This study will evaluate the influence of sleep apnea on clinical and radiological features of MS. Sleep apnea is associated with hypoxemia during sleep, which is likely detrimental to MS. Clinical data (MRI, lab results, medical history, labs, and sleep studies) of MS patients will be collected and...
What is the current status of trial NCT04603196?
This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2019-06-20. Estimated completion is 2030-06-20.
What conditions does trial NCT04603196 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Obstructive Sleep Apnea.
Who is sponsoring clinical trial NCT04603196?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04603196 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04603196's enrollment target sits among peer trials
800 35th of 315 higher than 281 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI